Insulet Corporation (NASDAQ:PODD) showcases a strong financial performance with a ROIC of 16.28% and a WACC of 10.24%, indicating efficient capital use.
Compared to peers like DexCom and Tandem Diabetes Care, Insulet demonstrates superior capital efficiency with a ROIC to WACC ratio of 1.59.
Insulet’s performance, particularly in generating returns well above its cost of capital, positions it as a leader in the competitive diabetes care market.

Insulet Corporation (NASDAQ:PODD) is a medical device company known for its innovative insulin management systems, particularly the Omnipod Insulin Management System. This system offers a tubeless, wearable insulin pump that simplifies diabetes management. Insulet competes with companies like DexCom, Tandem Diabetes Care, and others in the diabetes care market.
In evaluating Insulet’s financial performance, the Return on Invested Capital (ROIC) and Weighted Average Cost of Capital (WACC) are key metrics. Insulet’s ROIC of 16.28% compared to its WACC of 10.24% results in a ROIC to WACC ratio of 1.59. This indicates that Insulet is effectively using its capital to generate returns well above its cost of capital.
When compared to its peers, Insulet stands out. DexCom, for instance, has a ROIC of 10.20% and a WACC of 9.58%, resulting in a ROIC to WACC ratio of 1.07. This suggests that while DexCom is generating returns above its cost of capital, it is not as efficient as Insulet.
Tandem Diabetes Care and Masimo Corporation both have negative ROIC to WACC ratios, with Tandem at -1.49 and Masimo at -1.54. This indicates that these companies are not generating sufficient returns to cover their cost of capital, highlighting Insulet’s superior capital efficiency.
ShockWave Medical, with a ROIC to WACC ratio of 1.15, shows good efficiency but still falls short of Insulet’s performance. Insulet’s ability to generate returns significantly above its cost of capital positions it as a leader in its industry.